OSI-7904L for Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

This is a study looking into the safety and effectiveness of a drug called OSI-7904L for treating advanced stomach or gastroesophageal junction (GEJ) adenocarcinoma, a type of cancer. The study focuses on individuals with these specific types of cancer. The goal is to find new ways to help these patients, as current treatments may not be working well enough or have side effects that are hard to handle. During this study, participants will receive OSI-7904L as a single agent treatment. If they don't show improvement after two cycles, they may switch to a different, commonly used combination of drugs. The study will monitor the participants' health to see how well the treatment works and if there are any side effects. It's important to note that participants might experience benefits or risks associated with this treatment, as with any clinical trial.